ISSN: 2167-0420
Karlygash N. Tazhibayeva , Assel D. Sadykova, Galiya E. Kaldygozova, Almas N. Ormanov, Bolat B. Daurenov, Alizada F. Kuliev, Aiman A. Mussina
The issue of early detection of oncological diseases by specialists in the general clinical network is very relevant. Oncological diseases are detected only at 9-9.6% of preventive examinations in the Republic of Kazakhstan. The purpose of the study was to substantiate the need for a comprehensive program for the early detection of malignant manifestations of visual localization, to develop, implement and evaluate its effectiveness. The study was divided into 3 areas. During the first referral, out of 11,200 patients registered in the regional oncological dispensary, 5,874 patients were referred to patients of working age, N=1,696 patients were selected. The final sample consisted of 1669 patients. The control group included N=1754 able-bodied patients who applied to the clinic. The second group consisted of N=600 district doctors of district and city polyclinics of the South Kazakhstan region. The third area of research is the medical records of patients who underwent oncological screening, as well as medical records with N=15,111 registered medical records in multidisciplinary hospitals over the past 10 years. Informed consent to participate in the study was obtained from patients of working age (16-62 years).
As a result of the study, we came to the following conclusion
The dynamics of the cancer incidence rate among residents of working age in Shymkent for 2006-2016 showed an increase from 197.9%00 to 203.7%00, the highest cancer incidence rate was registered in the age group of 49-59 years, an increase in cancer incidence 2; Show an increase of 9 percent. It was found that mortality increased from 199.2 %00 to 202.1 %00. Disability was 21.6%. Cancer screening conducted in Shymkent in the period from 2012 to 2016 shows an improvement in the level of detection of cancer from year to year. The inhabitants of the target group were tested according to the plan. But the detection of oncological pathologies in stages I and II still gives a low rate